Assembly Biosciences Inc (NASDAQ:ASMB) Receives $53.67 Average PT from Analysts

Assembly Biosciences Inc (NASDAQ:ASMB) has been given an average rating of “Hold” by the eight research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $53.67.

ASMB has been the topic of a number of recent analyst reports. William Blair reissued a “buy” rating on shares of Assembly Biosciences in a research report on Tuesday, July 16th. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday. Chardan Capital reaffirmed a “hold” rating on shares of Assembly Biosciences in a research report on Sunday, June 30th. Finally, Zacks Investment Research lowered shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th.

A number of hedge funds have recently made changes to their positions in ASMB. FMR LLC increased its position in Assembly Biosciences by 136.0% during the fourth quarter. FMR LLC now owns 443,036 shares of the biopharmaceutical company’s stock worth $10,021,000 after acquiring an additional 255,336 shares during the period. Emerald Advisers LLC increased its position in Assembly Biosciences by 20.3% during the first quarter. Emerald Advisers LLC now owns 468,379 shares of the biopharmaceutical company’s stock worth $9,222,000 after acquiring an additional 79,039 shares during the period. BlackRock Inc. increased its position in Assembly Biosciences by 3.4% during the fourth quarter. BlackRock Inc. now owns 1,909,510 shares of the biopharmaceutical company’s stock worth $43,193,000 after acquiring an additional 63,554 shares during the period. Emerald Mutual Fund Advisers Trust increased its position in Assembly Biosciences by 13.3% during the first quarter. Emerald Mutual Fund Advisers Trust now owns 418,143 shares of the biopharmaceutical company’s stock worth $8,233,000 after acquiring an additional 49,230 shares during the period. Finally, Tibra Equities Europe Ltd bought a new position in Assembly Biosciences during the first quarter worth $918,000. 86.23% of the stock is currently owned by institutional investors and hedge funds.

ASMB traded up $0.05 during midday trading on Friday, hitting $11.91. 49,867 shares of the company’s stock traded hands, compared to its average volume of 232,138. The stock has a market capitalization of $303.02 million, a P/E ratio of -2.99 and a beta of 1.44. The company’s fifty day moving average price is $13.40. The company has a current ratio of 7.97, a quick ratio of 7.97 and a debt-to-equity ratio of 0.06. Assembly Biosciences has a one year low of $11.49 and a one year high of $44.54.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.06) by $0.01. Assembly Biosciences had a negative net margin of 671.48% and a negative return on equity of 56.45%. The company had revenue of $3.89 million for the quarter, compared to analyst estimates of $3.81 million. On average, equities analysts forecast that Assembly Biosciences will post -4.34 earnings per share for the current fiscal year.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.

Recommended Story: What does a bar chart mean for investors?

Analyst Recommendations for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.